TransMedics Group, Inc. (NASDAQ:TMDX) Stake Boosted by Graham Capital Management L.P.

Graham Capital Management L.P. increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 610.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,956 shares of the company's stock after acquiring an additional 26,596 shares during the period. Graham Capital Management L.P. owned approximately 0.09% of TransMedics Group worth $1,930,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of TMDX. Vanguard Group Inc. grew its stake in shares of TransMedics Group by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company's stock worth $226,700,000 after purchasing an additional 40,860 shares in the last quarter. FIL Ltd boosted its position in shares of TransMedics Group by 28.0% during the 4th quarter. FIL Ltd now owns 1,000,358 shares of the company's stock worth $62,372,000 after acquiring an additional 218,961 shares in the last quarter. Braidwell LP purchased a new position in shares of TransMedics Group in the 4th quarter valued at about $57,493,000. Geode Capital Management LLC raised its position in shares of TransMedics Group by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 772,744 shares of the company's stock worth $48,191,000 after acquiring an additional 8,954 shares in the last quarter. Finally, Wasatch Advisors LP increased its stake in TransMedics Group by 83.3% in the fourth quarter. Wasatch Advisors LP now owns 441,354 shares of the company's stock valued at $27,518,000 after purchasing an additional 200,603 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TMDX shares. Oppenheimer lifted their price target on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Piper Sandler reiterated an "overweight" rating and issued a $125.00 price objective (up previously from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Wednesday, April 23rd. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Three analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $126.70.

Insiders Place Their Bets

In other news, Director Edward M. Basile sold 6,000 shares of the company's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $115.63, for a total value of $693,780.00. Following the completion of the sale, the director now owns 732 shares of the company's stock, valued at $84,641.16. This represents a 89.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.00% of the stock is owned by insiders.

TransMedics Group Price Performance

TransMedics Group stock traded down $0.55 during mid-day trading on Thursday, hitting $121.81. 957,565 shares of the company were exchanged, compared to its average volume of 1,354,809. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The company has a market capitalization of $4.12 billion, a P/E ratio of 129.59 and a beta of 1.91. The business's 50 day simple moving average is $81.79 and its two-hundred day simple moving average is $75.70. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, beating analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. During the same quarter in the previous year, the business earned $0.35 earnings per share. The business's revenue for the quarter was up 48.2% on a year-over-year basis. Analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.